WORCESTER, Mass., Nov. 5, 2008 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com) , the leader in drug delivery for metabolic diseases through the inner lining of the mouth, is currently featured on the XM Satellite Radio program "ReachMD."
Bruce Japsen, pharmaceuticals and biotechnology reporter at the Chicago Tribune, interviewed Dr. Gerald Bernstein, vice president for medical affairs of Generex, about the company's flagship product Oral-lyn(tm). Dr. Bernstein gives a detailed and insightful interview placing significant emphasis on the growing global epidemic of diabetes and how Generex's pioneering oral drug delivery platform RapidMist(tm) and Oral-lyn(tm) oral insulin can meet the need for more accessible and practical insulin treatment.
Excerpt from the interview:
Japsen: "Where are we heading with the new treatments for diabetes?" Bernstein: "Our product (Oral-lyn) is designed to offer a safe and convenient alternative to prandial insulin injections which can improve treatment compliance and quality of life for patients with diabetes..."
To listen to the interview, please visit the Generex Biotechnology website at www.generex.com, scroll down to the "ReachMD" icon, and click on the icon to activate the interview. Dr. Bernstein's interview was originally broadcast on Monday and will be rebroadcast on XM Satellite Radio Channel 157 at the following times (all times Eastern):
Wednesday, Nov. 5 10:15 AM, 10:15 PM Thursday, Nov. 6 8:15 AM, 8:15 PM Friday, Nov. 7 6:15 AM, 6:15 PM
About Generex Biotechnology Corporation
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(tm) device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)), which is available for sale in Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes and which was approved for sale in India in October 2007, is in Phase III clinical trials at several sites around the world. For more information, visit the Generex website at http://www.generex.com.
The Generex Biotechnology Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3831
Safe Harbor Statement
This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.